Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Celcuity Inc
(NQ:
CELC
)
17.35
+0.47 (+2.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Celcuity Inc
< Previous
1
2
Next >
Celcuity Inc. Announces $50 Million Private Placement
October 18, 2023
Via
ACCESSWIRE
Celcuity Set to Join Russell 2000 and 3000 Indexes
June 20, 2023
Via
ACCESSWIRE
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 24, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 15, 2023
Via
ACCESSWIRE
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
May 12, 2023
Via
ACCESSWIRE
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
September 14, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
May 08, 2023
Via
ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
April 18, 2023
Via
ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
March 16, 2023
Via
ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
March 15, 2023
Via
ACCESSWIRE
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
March 01, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023
Via
ACCESSWIRE
Celcuity Closes $100 Million Private Placement
December 12, 2022
Via
ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
December 09, 2022
Via
ACCESSWIRE
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
December 07, 2022
Via
ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
November 22, 2022
Via
ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
November 03, 2022
Via
ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
August 04, 2022
Via
ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
Via
ACCESSWIRE
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today...
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast...
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Celcuity Inc. Announces $100 Million Private Placement
May 16, 2022
Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
May 09, 2022
MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.